Peripheral NK and B regulatory cell frequencies are altered with symptomatic exacerbation in generalized myasthenia gravis patients

Xiao-Yin Lai1,2, Meng-Cui Gui1, Jing Lin1, Yue Li1, Xuan Luo3, Long-Xuan Li2, Bi-Tao Bu1

1Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China. 2Department of Neurology, Gongli Hospital, Pudong New Area, Shanghai 200135, China. 3Teaching and Research Office of Hygiene, 95890 Unit, Chinese People’s Liberation Army, Wuhan 430000, Hubei, China.

Correspondence to: Dr. Bi-Tao Bu, Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave., Wuhan 430030, Hubei, China. E-mail: bubitao@tjh.tjmu.edu.cn; Dr. Long-Xuan Li, Department of Neurology, Gongli Hospital, 219 Miaopu Road, Pudong New Area, Shanghai 200135, China. E-mail: Longxuanlee2006@yahoo.com

How to cite this article: Lai XY, Gui MC, Lin J, Li Y, Luo X, Li LX, Bu BT. Peripheral NK and B regulatory cell frequencies are altered with symptomatic exacerbation in generalized myasthenia gravis patients. Neuroimmunol Neuroinflammation 2017;4:179-87.

ABSTRACT

Aim: Myasthenia gravis (MG) is an autoimmune disease, in which immunotherapy can improve symptoms for a period, but the majority of patients still experience symptomatic fluctuation or develop myasthenic crisis. This study aimed to explore the relationship between frequency of peripheral lymphocyte subsets and myasthenia gravis disease stage. Methods: The percentages of B regulatory (Breg) cells and natural killer (NK) cells in the peripheral...
blood samples obtained from 54 MG patients and 10 healthy controls were surveyed using flow cytometry. MG patients were subdivided into the ocular MG, generalized MG (GMG) in exacerbation stage and GMG in remission stage. Results: The percentage of Breg cells was significantly decreased in both the exacerbation stage (6.93 ± 1.18) and remission stage (6.56 ± 1.32) of GMG patients compared to healthy controls (15.97 ± 2.88). The percentage of NK cells were significantly increased in GMG patients in remission stage (20.69 ± 3.45) compared to healthy controls (11.33 ± 0.95). Frequency of NK cells in the patients in remission stage was significantly increased compared to patients in exacerbation (20.69 ± 3.45 vs. 12.32 ± 1.42). Conclusion: The Breg cells are involved in the pathogenesis of GMG, and NK cells are closely associated with the fluctuation of MG symptoms. NK cells could be a useful marker for MG activity and for monitoring effectiveness of immunotherapy.

INTRODUCTION

Myasthenia gravis (MG) is one of the most common autoimmune neurological diseases and affects the neuromuscular junction.[1] Although there are many therapeutic methods such as immunosuppressive therapy and steroids which are generally regarded as the effective preventive measures leading to marked symptomatic improvement in the majority of MG patients, there are many cases who still experience fluctuating muscle weakness and fatigability to some degree, or develop myasthenic crisis even after a clinical remission.[2-5] Yet the factors predicting the symptomatic fluctuation have not been well defined.

MG is mainly mediated by acetylcholine receptor antibodies (AChR-Ab), which were demonstrated to be associated with the severity of disease in individuals.[6] However, the heterogeneity of AChR-Ab and no elevated titers of AChR-ab in the minority of MG patients limited the clinical significance of measuring the antibodies.[1,7] In addition, there are some patients with elevated titers of antibodies against muscle-specific kinase (MuSK), Titin, RyR and LRP4,[8-11] signifying the heterogeneity of the autoimmune disease. Identification of specific markers of disease activity and severity is of great interest to clinicians. Changes in peripheral lymphocyte subsets were reported in patients with MG as well as patients with other autoimmune diseases, including systemic lupus erythematosus,[12] rheumatoid arthritis[13] and Sjogren’s syndrome,[14,15] suggesting that these abnormal distributions of lymphocyte subsets may be involved in the pathogenesis of autoimmune diseases.[16-18] CD4+ T helper cells have an important role in an experimental animal model of myasthenia gravis (EAMG) and MG patients as they influence autoreactive B cell production of anti-AChR antibodies.[20] Th1, Th2, Th17 and regulatory T (Treg) cells, which were differentiated from Naïve CD4+ T cells, have been shown to be involved in the pathogenesis of MG.[21] B cells, because of the key contribution to humoral immune responses involving the secretion of antibodies, are generally considered to be pathogenic in the majority of autoimmune diseases. Recent evidence indicates that specific B cell subsets can negatively regulate immune responses by constraining Th1 and Th17 responses, indicative of the existence of regulatory B (Breg) cells.[22] Natural killer (NK) cells predominantly participate in the innate immune response to infections. NK cell-derived interferon-gamma activates Th1 helper cells,[23] and NK cells can impact acquired immunity. The subsets of lymphocytes mentioned above have been demonstrated to be involved in the pathogenesis of MG, but the role of lymphocyte subsets in symptomatic exacerbation in MG patients is not fully understood.

NK cells which play an important role during viral infection and tumor diseases, were considered to be involved in the regulation of autoimmunity in animal models and in humans,[24-26] NK cell numbers were found to decline with progression of most autoimmune diseases of humans.[27-29] Interestingly, the number of NK cells was increased significantly after plasmapheresis in patients with MG, indicating that they may become an important marker for monitoring clinical activation in MG patients.[14]

Traditionally, B cells have been thought to contribute to the antigen (Ag)-specific autoantibody production. Nonetheless, the role of B cells extends beyond the production of antibodies in autoimmune diseases. Recently, B cell subsets with regulatory functions were identified and the studies focused on Breg cells, also known as B10 cells, which express IL-10 and CD1d+CD5+CD19+ phenotypes.[30-32] Recent studies showed that Breg cells can prevent the development of EAMG,[23] and were involved in patients with autoimmune diseases.[31,34-36] However, whether there are corresponding changes in Breg cells associated with severity of diseases remains elusive.

In this study, we investigated the changes in peripheral NK cells and Bregs in MG patients experiencing deterioration, in attempt to find a reliable marker
for MG activity and for monitoring effectiveness of immunotherapy.

METHODS

Patients
In this study, 54 patients with MG who met the standard clinical criteria\[37\] and 10 healthy controls (HC), 4 men and 6 women, aged 38.50 ± 16.37. All the participants signed the informed consent prior to the enrollment. The study was performed in accordance with the 1964 Declaration of Helsinki (including amendments) and has been approved by the Ethics Committee of Huazhong University of Science and Technology. Exclusion criteria were severe heart diseases, severe kidney diseases, severe mental illness, acute or chronic hepatitis, tuberculosis or HIV infection. The mean ± standard deviation of the ages of the patients was 40.30 ± 14.81 years. The sex ratio (male:female) was 28:15. The clinical features of the participants were summarized in Table 1. Eleven patients presented with ocular MG (OMG) (age: 35.36 ± 4.57; sex ratio: 5:6), and 43 with generalized MG (GMG). The GMG patients were further divided into two groups according to the clinical status. Group I included 25 patients who were in exacerbation stage (PE), presenting symptomatic exacerbation or myasthenic crisis (age: 44.52 ± 2.58; sex ratio: 8:17). Group II consisted of 18 patients who were in remission (PR), manifesting slight limb weakness or ocular symptoms for at least three months (age: 35.44 ± 3.66; sex ratio: 7:11). Overall, 43 patients were on prednisone and trans-sternal extended thymectomy was performed on 30 patients, including 8 with thymic hyperplasia and 22 with thymoma. The identified factors which provoked the deterioration of MG symptoms were upper respiratory tract infection (14 cases), inappropriate drug use (4 cases), surgery (1), exhaustion (1), and stress (1) [Table 2].

Flow cytometric analysis
The peripheral blood samples from all the participants were obtained by venipuncture and stored in tubes containing ethylene diamine tetraacetic acid (5.4 mg/tube). Each sample was divided into 2 tubes, each one containing 100 µL fresh whole blood which was further incubated with 5 µL of mAbs (Becton Dickinson) for 20 min in dark at room temperature. Breg cells were stained with FITC conjugated anti-human CD19, PE conjugated anti-human CD1d, APC conjugated anti-human CD5, and NK cells were analyzed after staining with PE conjugated anti-human CD16, PerCP conjugated anti-human CD3, APC conjugated anti-human CD56, respectively. Isotype-matched immunoglobulin served as control for analysis of CD1d+CD5+CD19+B cells and CD3-CD16+CD56+NK cells. After incubation, erythrocytes were lysed with FACS lysing solution (Becton Dickinson). The remaining cells were resuspended in PBS then at least 30,000 lymphocyte events were acquired from each tube to determine their proportions using the FACS Caliber flow cytometer (Becton Dickinson).

Statistical analysis
All statistical analyses were performed using the SPSS software application. The data were expressed as the mean ± standard error. For a comparison of the different subgroups of the MG patients and the healthy controls, the data were analyzed using two-tailed Student’s t-test. P-values lower than 0.05 were considered to be statistically significant.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients in exacerbation (number)</th>
<th>Patients in remission (number)</th>
<th>Ocular MG (number)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>17</td>
<td>11</td>
<td>6</td>
</tr>
<tr>
<td>Male</td>
<td>8</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Age (year, mean ± SD)</td>
<td>44.52 ± 2.58</td>
<td>35.44 ± 3.66</td>
<td>35.36 ± 4.57</td>
</tr>
<tr>
<td>Osserman's classification</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class I</td>
<td></td>
<td></td>
<td>11</td>
</tr>
<tr>
<td>Class IIa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class IIb</td>
<td>1</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Class III</td>
<td>21</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Class IV</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thymoma</td>
<td>9</td>
<td>11</td>
<td>2</td>
</tr>
<tr>
<td>With thymectomy</td>
<td>6</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Thymic hyperplasia</td>
<td>1</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>With thymectomy</td>
<td>3</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Use of prednisone</td>
<td>24</td>
<td>17</td>
<td>2</td>
</tr>
<tr>
<td>Immunosuppressant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MG: myasthenia gravis; SD: standard deviation
RESULTS

Frequencies of Breg cells decreased in the peripheral blood of GMG patients

We have analyzed the frequencies of peripheral Breg cells in the MG patients. CD19\(^+\)CD1d\(^+\)CD5\(^-\) B cells are routinely regarded as Bregs. To characterize the Breg cell subpopulation, we have determined their surface expression of CD1d and CD5 with CD19 gating, the 2 markers that are believed to be co-expressed by “regulatory” B cells.\(^{[38]}\) The data revealed that the percentage of CD1d\(^+\)CD5\(^-\) cells among the CD19\(^+\) cells was increased to different degrees, especially in GMG patients in remission stage (20.69 ± 3.45) compared to healthy controls (11.33 ± 0.95; \(P = 0.017\)). In the patients with OMG, who presented with mild symptoms, NK cells tended to increase compared with those in the healthy controls (18.98 ± 3.81). Yet the increase was less than that in GMG patients in remission stage and there was no statistical difference. The percentage of NK cells in the GMG patients at exacerbation stage also tended to increase, but the difference was not significant when compared with that in the healthy controls (12.32 ± 1.42). In order to determine whether NK cell frequencies were associated with symptomatic exacerbation, the percentages of NK cells were compared between the two subgroups of GMG patients. The frequency of NK cells in the patients in remission were significantly increased compared to patients in exacerbation (20.69 ± 3.45 vs. 12.32 ± 1.42, \(P = 0.017\), Table 4, Figure 2). The data suggest that NK cells are involved in the pathogenesis of MG and mayplay a protective role during development of the disease.

Frequency of lymphocyte subsets in patients with exacerbation and infection

It’s well known that various factors such as infections, inappropriate drug use, or neuro-endocrine dysfunction

Table 2: Factors leading to exacerbation

<table>
<thead>
<tr>
<th>Factor</th>
<th>Number</th>
<th>Ratio (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection</td>
<td>14</td>
<td>56</td>
</tr>
<tr>
<td>Inappropriate drug use</td>
<td>4</td>
<td>16</td>
</tr>
<tr>
<td>Unknown cause</td>
<td>4</td>
<td>16</td>
</tr>
<tr>
<td>Surgery</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Exhaustion</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Stress</td>
<td>1</td>
<td>4</td>
</tr>
</tbody>
</table>

Table 3: Frequencies of Breg cells in the peripheral blood of MG patients (%)

<table>
<thead>
<tr>
<th>Group</th>
<th>Number</th>
<th>CD19(^+)CD1d(^+)CD5(^-) B cells</th>
<th>(P) value(^a)</th>
<th>(P) value(^b)</th>
<th>(P) value(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients in exacerbation</td>
<td>25</td>
<td>6.93 ± 1.18</td>
<td>0.834</td>
<td>0.001</td>
<td>0.001</td>
</tr>
<tr>
<td>Patients in remission</td>
<td>18</td>
<td>6.56 ± 1.32</td>
<td></td>
<td>0.002</td>
<td>0.002</td>
</tr>
<tr>
<td>Ocular MG</td>
<td>11</td>
<td>16.08 ± 2.88</td>
<td></td>
<td>0.978</td>
<td></td>
</tr>
<tr>
<td>Healthy controls</td>
<td>10</td>
<td>15.97 ± 2.88</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CD1d\(^+\) CD5\(^-\) represent the Breg cells; the results represent the mean ± standard error; \(P\) value\(^a\) as compared between the patients in exacerbation and patients in remission; \(P\) value\(^b\) as compared with ocular MG; \(P\) value\(^c\) as compared with healthy controls. MG: myasthenia gravis

Table 4: Frequencies of NK cells in the peripheral blood of MG patients (%)

<table>
<thead>
<tr>
<th>Group</th>
<th>Number</th>
<th>CD3(^+)CD19(^+)CD56(^+) NK cells</th>
<th>(P) value(^a)</th>
<th>(P) value(^b)</th>
<th>(P) value(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients in exacerbation</td>
<td>25</td>
<td>12.32 ± 1.42</td>
<td>0.017</td>
<td>0.126</td>
<td>0.569</td>
</tr>
<tr>
<td>Patients in remission</td>
<td>18</td>
<td>20.69 ± 3.45</td>
<td></td>
<td>0.751</td>
<td>0.017</td>
</tr>
<tr>
<td>Ocular MG</td>
<td>11</td>
<td>18.98 ± 3.81</td>
<td></td>
<td>0.077</td>
<td></td>
</tr>
<tr>
<td>Healthy controls</td>
<td>10</td>
<td>11.33 ± 0.95</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CD3\(^+\)CD19\(^+\) CD56\(^+\) cells represent the NK cells. The results represent the mean ± standard error; \(P\) value\(^a\) as compared between the patients in exacerbation and ones in remission; \(P\) value\(^b\) as compared with ocular MG patients; \(P\) value\(^c\) as compared with the healthy controls. NK: natural killer; MG: myasthenia gravis
will lead to muscle weakness in MG patients. Among the predisposing factors, infections were the most frequently identified for symptomatic exacerbation in our study [Table 5]. So, we have further analyzed peripheral blood lymphocyte subsets in the patients with infections at the exacerbation stage. Our data showed that the patients with infections had significantly lower percentage of NK cells those without infections during exacerbation (10.97 ± 1.74; 14.03 ± 2.36, Table 5, Figure 3), suggesting that the NK cells may be consumed by infections or by a similar mechanism during deterioration of muscle weakness. Furthermore, the difference in NK cells percentages between the patients in exacerbation with infections and the cases in remission was significant ($P = 0.028$), but the difference between the patients in exacerbation without infections and the cases in remission was not statistically significant [Table 5; Figure 3]. The

| Table 5: Frequencies of NK and Breg cells in PE with infection and without infection (%) |
|-----------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| **Group**                                      | **Breg cells**      | **NK cells**        | **Group**                                      | **Breg cells**      | **NK cells**        |
|                                               | **Frequencies**     | **P value**         | **Frequencies**     | **P value**         | **Frequencies**     | **P value**         |
|                                               | $\pm$ standard error | $^a$                | $\pm$ standard error | $^c$                | $\pm$ standard error | $^d$                |
| PE with infection (14)                         | 6.84 ± 1.59         | 0.891               | 0.007               | 0.931               | 10.97 ± 1.74        | 0.028               | 0.871               | 0.295               |
| PE without infection (11)                      | 7.05 ± 1.85         | 0.825               | 0.016               | 14.03 ± 2.36        | 0.177               | 0.307               | 0.307               |
| Patients in remission (18)                     | 6.56 ± 1.32         | 0.002               | 20.69 ± 3.45        | 0.017               |
| Healthy controls (10)                          | 15.97 ± 2.88        | 11.33 ± 0.95        |

The results represent the mean ± standard error; $P$ value$^a$ as compared between the patients in exacerbation and the ones in remission; $P$ value$^c$ as compared with the healthy controls. $P$ value$^d$ as compared between PE patients with infection and without infection. NK: natural killer; PE: patients in exacerbation.

Figure 1: (A) Breg cells flow cytometry scatter plot in the PE, PR, OMG patients and the HC; (B) the percentage of Breg cells in GMG significantly lower than those in the OMG patients and in the controls, the difference was statistically significant ($P < 0.05$), but there was no obvious difference between the two subgroups of GMG patients. PE: patients in exacerbation; PR: patients in remission; OMG: ocular myasthenia gravis; HC: healthy controls; GMG: generalized myasthenia gravis.

Figure 2: (A) NK cells flow cytometry scatter plot in the PE, PR, OMG patients and the HC; (B) the percentage of NK cells in the patients remission significantly higher than that in the patients in exacerbation and the healthy controls ($P < 0.05$). NK: natural killer; PE: patients in exacerbation; PR: patients in remission; OMG: ocular myasthenia gravis; HC: healthy controls.
percentage of Bregs did not differ between the patients in exacerbation with infections (6.84 ± 1.59) and those without infections (7.05 ± 1.85).

DISCUSSION

Disorders of neuromuscular junction can be of immunological, toxic, or genetic origin; and among these rare disorders, MG is the most common. The clinical hallmark of MG is a fluctuating weakness and fatigability of the affected voluntary muscles. With the advent of immunotherapy, the long-term outcome has been improved significantly, but the symptomatic deterioration after symptomatic remission takes place in majority of MG patients including both the OMG and GMG cases. Thus, reliable markers that reflect the activity of the disease to guide the clinical therapy are critical.

MG patients present with heterogeneous clinical patterns in terms of onset-age, initial symptoms, mode of development, thymic abnormalities, immunological profiles, and responsiveness to treatment. MG is currently considered to consist of a heterogeneous group of autoimmune diseases, which share common aspects, such as the impairment of neuromuscular transmission induced by autoimmunity, manifested by muscle weakness and fatigability and the response to both pyridostigmine and immunosuppressants.

In MG, the presence of multiple autoantibodies against numerous targeted molecules (e.g. AChR-ab). These antibodies suggest altered immunity, but any single antibody determination is hardly reflective of the progression or activity of the disease. The production of the above-mentioned antibodies are likely the result of the dysfunctional lymphocytes, thus measuring the peripheral lymphocytes subsets in MG patients may be a promising way to monitor the progression of the disease.

B cell abnormalities contribute to the development and progress of autoimmune diseases. Traditionally, the predominant function of B cells was thought to be limited to production of autoantibodies. However, B cells have both positive and negative regulatory roles during immune responses. During murine development the absence of B cells results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocytes numbers, defects within spleen dendritic cells and T cells compartments. Through production of immunomodulatory cytokines, B cells can also negatively regulate cellular immune responses. A variety of regulatory B cell subsets have been described. Whether Breg cells can serve as a marker for disease activity in MG remains to be determined.

In MG, the presence of multiple autoantibodies against numerous targeted molecules (e.g. AChR-ab). These antibodies suggest altered immunity, but any single antibody determination is hardly reflective of the progression or activity of the disease. The production of the above-mentioned antibodies are likely the result of the dysfunctional lymphocytes, thus measuring the peripheral lymphocytes subsets in MG patients may be a promising way to monitor the progression of the disease.

B cell abnormalities contribute to the development and progress of autoimmune diseases. Traditionally, the predominant function of B cells was thought to be limited to production of autoantibodies. However, B cells have both positive and negative regulatory roles during immune responses. During murine development the absence of B cells results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocytes numbers, defects within spleen dendritic cells and T cells compartments. Through production of immunomodulatory cytokines, B cells can also negatively regulate cellular immune responses. A variety of regulatory B cell subsets have been described. Whether Breg cells can serve as a marker for disease activity in MG remains to be determined.

In MG, the presence of multiple autoantibodies against numerous targeted molecules (e.g. AChR-ab). These antibodies suggest altered immunity, but any single antibody determination is hardly reflective of the progression or activity of the disease. The production of the above-mentioned antibodies are likely the result of the dysfunctional lymphocytes, thus measuring the peripheral lymphocytes subsets in MG patients may be a promising way to monitor the progression of the disease.

B cell abnormalities contribute to the development and progress of autoimmune diseases. Traditionally, the predominant function of B cells was thought to be limited to production of autoantibodies. However, B cells have both positive and negative regulatory roles during immune responses. During murine development the absence of B cells results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocytes numbers, defects within spleen dendritic cells and T cells compartments. Through production of immunomodulatory cytokines, B cells can also negatively regulate cellular immune responses. A variety of regulatory B cell subsets have been described. Whether Breg cells can serve as a marker for disease activity in MG remains to be determined.

In MG, the presence of multiple autoantibodies against numerous targeted molecules (e.g. AChR-ab). These antibodies suggest altered immunity, but any single antibody determination is hardly reflective of the progression or activity of the disease. The production of the above-mentioned antibodies are likely the result of the dysfunctional lymphocytes, thus measuring the peripheral lymphocytes subsets in MG patients may be a promising way to monitor the progression of the disease.

B cell abnormalities contribute to the development and progress of autoimmune diseases. Traditionally, the predominant function of B cells was thought to be limited to production of autoantibodies. However, B cells have both positive and negative regulatory roles during immune responses. During murine development the absence of B cells results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocytes numbers, defects within spleen dendritic cells and T cells compartments. Through production of immunomodulatory cytokines, B cells can also negatively regulate cellular immune responses. A variety of regulatory B cell subsets have been described. Whether Breg cells can serve as a marker for disease activity in MG remains to be determined.

In MG, the presence of multiple autoantibodies against numerous targeted molecules (e.g. AChR-ab). These antibodies suggest altered immunity, but any single antibody determination is hardly reflective of the progression or activity of the disease. The production of the above-mentioned antibodies are likely the result of the dysfunctional lymphocytes, thus measuring the peripheral lymphocytes subsets in MG patients may be a promising way to monitor the progression of the disease.

B cell abnormalities contribute to the development and progress of autoimmune diseases. Traditionally, the predominant function of B cells was thought to be limited to production of autoantibodies. However, B cells have both positive and negative regulatory roles during immune responses. During murine development the absence of B cells results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocytes numbers, defects within spleen dendritic cells and T cells compartments. Through production of immunomodulatory cytokines, B cells can also negatively regulate cellular immune responses. A variety of regulatory B cell subsets have been described. Whether Breg cells can serve as a marker for disease activity in MG remains to be determined.

In MG, the presence of multiple autoantibodies against numerous targeted molecules (e.g. AChR-ab). These antibodies suggest altered immunity, but any single antibody determination is hardly reflective of the progression or activity of the disease. The production of the above-mentioned antibodies are likely the result of the dysfunctional lymphocytes, thus measuring the peripheral lymphocytes subsets in MG patients may be a promising way to monitor the progression of the disease.

B cell abnormalities contribute to the development and progress of autoimmune diseases. Traditionally, the predominant function of B cells was thought to be limited to production of autoantibodies. However, B cells have both positive and negative regulatory roles during immune responses. During murine development the absence of B cells results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocytes numbers, defects within spleen dendritic cells and T cells compartments. Through production of immunomodulatory cytokines, B cells can also negatively regulate cellular immune responses. A variety of regulatory B cell subsets have been described. Whether Breg cells can serve as a marker for disease activity in MG remains to be determined.

In MG, the presence of multiple autoantibodies against numerous targeted molecules (e.g. AChR-ab). These antibodies suggest altered immunity, but any single antibody determination is hardly reflective of the progression or activity of the disease. The production of the above-mentioned antibodies are likely the result of the dysfunctional lymphocytes, thus measuring the peripheral lymphocytes subsets in MG patients may be a promising way to monitor the progression of the disease.

B cell abnormalities contribute to the development and progress of autoimmune diseases. Traditionally, the predominant function of B cells was thought to be limited to production of autoantibodies. However, B cells have both positive and negative regulatory roles during immune responses. During murine development the absence of B cells results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocytes numbers, defects within spleen dendritic cells and T cells compartments. Through production of immunomodulatory cytokines, B cells can also negatively regulate cellular immune responses. A variety of regulatory B cell subsets have been described. Whether Breg cells can serve as a marker for disease activity in MG remains to be determined.

In MG, the presence of multiple autoantibodies against numerous targeted molecules (e.g. AChR-ab). These antibodies suggest altered immunity, but any single antibody determination is hardly reflective of the progression or activity of the disease. The production of the above-mentioned antibodies are likely the result of the dysfunctional lymphocytes, thus measuring the peripheral lymphocytes subsets in MG patients may be a promising way to monitor the progression of the disease.

B cell abnormalities contribute to the development and progress of autoimmune diseases. Traditionally, the predominant function of B cells was thought to be limited to production of autoantibodies. However, B cells have both positive and negative regulatory roles during immune responses. During murine development the absence of B cells results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocytes numbers, defects within spleen dendritic cells and T cells compartments. Through production of immunomodulatory cytokines, B cells can also negatively regulate cellular immune responses. A variety of regulatory B cell subsets have been described. Whether Breg cells can serve as a marker for disease activity in MG remains to be determined.

In MG, the presence of multiple autoantibodies against numerous targeted molecules (e.g. AChR-ab). These antibodies suggest altered immunity, but any single antibody determination is hardly reflective of the progression or activity of the disease. The production of the above-mentioned antibodies are likely the result of the dysfunctional lymphocytes, thus measuring the peripheral lymphocytes subsets in MG patients may be a promising way to monitor the progression of the disease.

B cell abnormalities contribute to the development and progress of autoimmune diseases. Traditionally, the predominant function of B cells was thought to be limited to production of autoantibodies. However, B cells have both positive and negative regulatory roles during immune responses. During murine development the absence of B cells results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocytes numbers, defects within spleen dendritic cells and T cells compartments. Through production of immunomodulatory cytokines, B cells can also negatively regulate cellular immune responses. A variety of regulatory B cell subsets have been described. Whether Breg cells can serve as a marker for disease activity in MG remains to be determined.

In MG, the presence of multiple autoantibodies against numerous targeted molecules (e.g. AChR-ab). These antibodies suggest altered immunity, but any single antibody determination is hardly reflective of the progression or activity of the disease. The production of the above-mentioned antibodies are likely the result of the dysfunctional lymphocytes, thus measuring the peripheral lymphocytes subsets in MG patients may be a promising way to monitor the progression of the disease.

B cell abnormalities contribute to the development and progress of autoimmune diseases. Traditionally, the predominant function of B cells was thought to be limited to production of autoantibodies. However, B cells have both positive and negative regulatory roles during immune responses. During murine development the absence of B cells results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocytes numbers, defects within spleen dendritic cells and T cells compartments. Through production of immunomodulatory cytokines, B cells can also negatively regulate cellular immune responses. A variety of regulatory B cell subsets have been described. Whether Breg cells can serve as a marker for disease activity in MG remains to be determined.

In MG, the presence of multiple autoantibodies against numerous targeted molecules (e.g. AChR-ab). These antibodies suggest altered immunity, but any single antibody determination is hardly reflective of the progression or activity of the disease. The production of the above-mentioned antibodies are likely the result of the dysfunctional lymphocytes, thus measuring the peripheral lymphocytes subsets in MG patients may be a promising way to monitor the progression of the disease.

B cell abnormalities contribute to the development and progress of autoimmune diseases. Traditionally, the predominant function of B cells was thought to be limited to production of autoantibodies. However, B cells have both positive and negative regulatory roles during immune responses. During murine development the absence of B cells results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocytes numbers, defects within spleen dendritic cells and T cells compartments. Through production of immunomodulatory cytokines, B cells can also negatively regulate cellular immune responses. A variety of regulatory B cell subsets have been described. Whether Breg cells can serve as a marker for disease activity in MG remains to be determined.
subclasses were similar among the control thymuses, hyperplasic thymuses and thymomas; suggesting that circulating NK cells may have migrated to sites of inflammation. In our study, we discovered that the percentage of NK cells was increased significantly in the patients in remission stage, but nearly unchanged in exacerbation stage and in PE with infections. The data suggest that NK cells may protect against autoimmune response, especially in patients with infections; yet, the mechanism for the increase in NK cells is unknown. These findings are consistent with Suzuki et al.,[30] which suggested that NK cells in the blood of patients at exacerbation stage may transfer to the neuromuscular junction, where immune cells obviously accumulate. At the stage of remission, NK cells might then transfer back to peripheral blood. It will be very interesting to compare the NK cell density in the neuromuscular junction among the patients in different stages. However, how the NK cells migrate at different stages and how NK cells are involved in the pathogenesis of MG remains to be fully elucidated. Based on our initial study, we also suggest that developing approaches that restore and boost the activity of NK cells may improve the MG symptoms and have therapeutic value.

Studies on the immune mechanism of OMG are scarce. However, in our study, both the Breg cells and NK cells were not obviously changed in the OMG patients. Actually, childhood onset MG (CMG), predominantly manifested isolated ocular symptoms, shows many different aspects from the adult onset MG, such as the rare transformation from the ocular type to generalized types, the scarcity of thymomas, and the lacking benefit of thymectomy in CMG.[41] We are convinced that the CMG with ocular type represents a different clinical entity in which the immunologic pathogenesis is far from being understood.

In conclusion, lymphocyte subsets were obviously disordered in GMG patients. The decrease of the peripheral Breg cells is linked with development of GMG, while the increase of peripheral NK cells is associated with reduced MG symptoms. Our research reveals that the frequency of the NK cells could be a reliable marker for MG activity in GMG patients. Restoring and boosting the activity of NK cells could be of therapeutic value. Therefore, a prospective, randomized clinical trial is required to further delineate the significance of NK cells in MG patients.

DECLARATIONS
Authors’ contributions
Concept, design, and manuscript review: B.T. Bu Concept, statistical analysis, and manuscript editing: L.X. Li Literature search, experimental studies, manuscript preparation, and manuscript editing: X.Y. Lai Clinical studies, and data acquisition: M.C. Gui, J. Lin, Y. Li, X. Luo, X.Y. Lai

Financial support and sponsorship
This study was supported by a grant from Natural Science Foundation of China to Dr. Bu (No. 81271320); the Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai (No. PWR12014-05); the Key Specialty Construction Project of Shanghai Municipal Health Bureau (No. ZK2015B16); the 100-Talents Program of the Shanghai Municipal Health Bureau (No. 2017BR051).

Conflicts of interest
There are no conflicts of interest.

Patient consent
All the participants signed the informed consent prior to the enrollment.

Ethics approval
The study has been approved by the Ethics Committee of Huazhong University of Science and Technology.

REFERENCES


46. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice.